康寧傑瑞(09966.HK)與蘇州康寧傑瑞就JSKN003項目及KN062新冠抗體項目技術開發合作
格隆匯5月26日丨康寧傑瑞(09966.HK)公吿,公司全資附屬公司江蘇康寧傑瑞生物製藥有限公司及蘇州康寧傑瑞生物科技有限公司於2021年5月26日就公司兩款候選藥物的技術開發項目訂立了兩份技術開發合同:(i)JSKN003的工藝開發項目(項目編號:JSKN003)及偶聯工藝關鍵原料mGalt1的製備工藝開發項目(項目編號:JSKN003e);及(ii)KN062新冠中和雙特異抗體開發項目。
根據行業慣例,公司委聘合約研究機構等相關服務供應商於臨牀前研究及臨牀試驗中提供若干服務。於公司招股章程中披露的重組前,江蘇康寧傑瑞為蘇州康寧傑瑞的附屬公司。蘇州康寧傑瑞自2018年以來一直為公司的可靠的服務提供者。因此其對公司的需求及要求十分熟悉。
此外,公司亦正積極擴大集團高度差異化的內部管線,加快公司核心產品及新型冠狀病毒疾病抗體藥物的研發。蘇州康寧傑瑞對於JSKN003工藝優化及KN062新冠抗體的技術開發擁有豐富的經驗和業界領先的能力。考慮到蘇州康寧傑瑞提供相關技術開發服務的品質、將來技術轉移的便捷性和保密性,以及就該等交易的報價與其他獨立第三方供應商相比更具競爭力,公司相信次合作有助於優化相關產品現有的生產工藝,降低生產成本,且會對公司相關產品研發、製造及商業化帶來積極影響。
公司董事(包括獨立非執行董事)認為,(i)JSKN003及KN062技術開發合同及其項下擬進行的交易按正常商業條款訂立,且協議的條款屬公平合理,及(ii)訂立JSKN003及KN062技術開發合同及其項下擬進行的交易乃於公司日常及一般業務過程中進行,符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.